Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more

Recent & Breaking News (NDAQ:URGN)

UroGen Pharma to Present at March 2019 Investor Conferences

Business Wire March 5, 2019

UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results

Business Wire February 28, 2019

UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019

Business Wire February 21, 2019

UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire January 28, 2019

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares

Business Wire January 23, 2019

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

Business Wire January 22, 2019

UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

Business Wire January 8, 2019

UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer

Business Wire January 3, 2019

UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

Business Wire December 17, 2018

Market Trends Toward New Normal in Zillow Group, YRC Worldwide, The Home Depot, UROGEN PHARMA, ZIOPHARM Oncology, and Cinedigm — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire December 3, 2018

UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment

Business Wire November 12, 2018

UroGen Pharma to Present at November 2018 Investor Conferences

Business Wire November 6, 2018

UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018

Business Wire November 5, 2018

FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma’s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

Business Wire October 30, 2018

UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Business Wire September 25, 2018

Jones “Woody” Bryan Joins UroGen Pharma as Senior Vice President of Business Development

Business Wire September 11, 2018

UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments  

GlobeNewswire August 14, 2018

UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

GlobeNewswire August 8, 2018

UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

GlobeNewswire August 7, 2018

UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)

GlobeNewswire July 11, 2018